New Approaches for the Identification and Characterization of Functional Markers of the Risk of E… (NCT02926547) | Clinical Trial Compass
CompletedNot Applicable
New Approaches for the Identification and Characterization of Functional Markers of the Risk of Extension of Breast Cancer Without Lymph Node Involvement
France108 participantsStarted 2014-03
Plain-language summary
1. Identify the tissue proteins associated with early breast cancer invasion phases without lymph node involvement .
2. Consider their role in the invasion and the risk of tumor spread .
Who can participate
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Breast cancer
* CCIS
* Invasive tumors
* Breast cancer tissues available in the biobank
Exclusion Criteria:
* non availability of cancer tissue specimen
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study was looking for proteins linked to early breast cancer invasion in cases without lymph node involvement — does my specific diagnosis fit that profile, and could the findings from this research be relevant to how my case is being assessed?
2Since this trial has already been completed, has my care team seen or reviewed any of its findings about those ten proteins, and could those results influence how they evaluate my risk of the cancer spreading?
3The trial focused on identifying biological markers rather than testing a treatment — does that mean results from this study might eventually change which tests or monitoring approaches are recommended for someone in my situation?
4Given that this was a characterization study and not a treatment trial, what are the current standard approaches for assessing spread risk in breast cancer without lymph node involvement, and how do they compare to what this research was exploring?
5Are there any follow-up studies or treatment trials building on this protein-marker research that my doctor thinks might be worth looking into based on my diagnosis?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
A list of the ten proteins most associated with early breast cancer invasion phases without lymph node involvement .